ProgramsView all programs
From the news
- Chancellor Amma Addresses the Parliament of World’s Religions
- Amrita Students Qualify for the European Mars Rover Challenge
Publication Type : Journal Article
Publisher : J Nanoparticle Res
Source : J Nanoparticle Res, Volume 17, Number 6, p.1-11 (2015)
Campus : Kochi
School : School of Pharmacy
Department : Pharmacology
Year : 2015
Abstract : Swami R, Singh I, Kulhari H, Jeengar MK, Khan W, Sistla R, “P-hydroxy benzoic acid conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation,”J Nanoparticle Res, vol. 17, no.6, pp. 1-11,2015[Abstract] Dendrimers which are discrete nanostructures/nanoparticles are emerging as promising candidates for many nanomedicine applications. Ligand-conjugated dendrimer facilitate the delivery of therapeutics in a targeted manner. Small molecules such as p-hydroxyl benzoic acid (pHBA) were found to have high affinity for sigma receptors which are prominent in most parts of central nervous system and tumors. The aim of this study was to synthesize pHBA-dendrimer conjugates as colloidal carrier for site-specific delivery of practically water insoluble drug, docetaxel (DTX) to brain tumors and to determine its targeting efficiency. pHBA, a small molecule ligand was coupled to the surface amine groups of generation 4-PAMAM dendrimer via a carbodiimide reaction and loaded with DTX. The conjugation was confirmed by 1HNMR and FT-IR spectroscopy. In vitro release of drug from DTX-loaded pHBA-conjugated dendrimer was found to be less as compared to unconjugated dendrimers. The prepared drug delivery system exhibited good physico-chemical stability and decrease in hemolytic toxicity. Cell viability and cell uptake studies were performed against U87MG human glioblastoma cells and formulations exerted considerable anticancer effect than plain drug. Conjugation of dendrimer with pHBA significantly enhanced the brain uptake of DTX which was shown by the recovery of a higher percentage of the dose from the brain following administration of pHBA-conjugated dendrimers compared with unconjugated dendrimer or formulation in clinical use (Taxotere®). Therefore, pHBA conjugated dendrimers could be an efficient delivery vehicle for the targeting of anticancer drugs to brain tumors.
Cite this Research Publication : Dr. Manish Kumar Jeengar, Swami R, Kulhari H, Singh I, Khan W, and Sistla R, “p-Hydroxy Benzoic Acid-conjugated Dendrimer Nanotherapeutics as Potential Carriers for Targeted Drug Delivery to Brain: An in Vitro and in vivo Evaluation”, J Nanoparticle Res, vol. 17, pp. 1-11, 2015.